Clinical trial
An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With…
NCT00206648 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00206648 |
|---|---|
| Title | An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS |
| Official title | A Randomized, Rater-blinded, Multicenter, Parallel-group Study Comparing the Efficacy and Safety of Betaseron 250 µg Subcutaneously Every Other Day With Avonex 30 µg Intramuscularly Once Per Week in Relapsing-remitting Multiple Sclerosis Patients Previously Treated With Avonex |
| Acronym | ABOVE |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis, Relapsing-Remitting |
| Intervention type | Drug |
| Interventions | Betaferon/Betaseron |
| Enrollment | 271 |
| Start date | Mar 1, 2003 |
| Completion | Oct 1, 2005 |
| First posted | Sep 21, 2005 |
| Last update posted | Dec 31, 2014 |
| Countries | Canada, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: